Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rezafungin acetate by Napp Pharmaceuticals for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia): Likelihood of Approval
Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)....
Rezafungin acetate by Napp Pharmaceuticals for Aspergillosis: Likelihood of Approval
Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Aspergillosis. According to GlobalData, Phase...
Rezafungin acetate by Napp Pharmaceuticals for Fungal Infections: Likelihood of Approval
Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Fungal Infections. According to GlobalData,...